Patents by Inventor Matthew Carl Allgeier

Matthew Carl Allgeier has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pharmaceutical compositions
    Patent number: 11918692
    Abstract: The present invention relates to solid oral fixed dose compositions of metformin, atorvastatin, and valsartan, or their pharmaceutically acceptable salts, processes for the preparation thereof, and the use of the composition to treat certain diseases.
    Type: Grant
    Filed: June 1, 2022
    Date of Patent: March 5, 2024
    Assignee: Eli Lilly and Company
    Inventors: Matthew Carl Allgeier, Tony Yantao Zhang
  • PHARMACEUTICAL COMPOSITIONS
    Publication number: 20220287978
    Abstract: The present invention relates to solid oral fixed dose compositions of metformin, atorvastatin, and valsartan, or their pharmaceutically acceptable salts, processes for the preparation thereof, and the use of the composition to treat certain diseases.
    Type: Application
    Filed: June 1, 2022
    Publication date: September 15, 2022
    Inventors: Matthew Carl ALLGEIER, Tony Yantao ZHANG
  • Pharmaceutical compositions
    Patent number: 11376223
    Abstract: The present invention relates to solid oral fixed dose compositions of metformin, atorvastatin, and valsartan, or their pharmaceutically acceptable salts, processes for the preparation thereof, and the use of the composition to treat certain diseases.
    Type: Grant
    Filed: July 10, 2018
    Date of Patent: July 5, 2022
    Assignee: Eli Lilly and Company
    Inventors: Matthew Carl Allgeier, Tony Yantao Zhang
  • PHARMACEUTICAL COMPOSITIONS
    Publication number: 20210137842
    Abstract: The present invention relates to solid oral fixed dose compositions of metformin, atorvastatin, and valsartan, or their pharmaceutically acceptable salts, processes for the preparation thereof, and the use of the composition to treat certain diseases.
    Type: Application
    Filed: July 10, 2018
    Publication date: May 13, 2021
    Inventors: Matthew Carl ALLGEIER, Tony Yantao ZHANG
  • Raf inhibitor compounds
    Patent number: 8741911
    Abstract: The present invention provides a pyrido[2,3-d]pyrimidine compound, or a pharmaceutically acceptable salt thereof, that inhibits Raf and, therefore, may be useful in treating cancer.
    Type: Grant
    Filed: March 5, 2013
    Date of Patent: June 3, 2014
    Assignees: Eli Lilly and Company, Deciphera Pharmaceuticals, LLC
    Inventors: Matthew Carl Allgeier, Daniel L. Flynn, Michael D. Kaufman, Phenil J. Patel, Craig D. Wolfangel
  • Raf Inhibitor Compounds
    Publication number: 20130252977
    Abstract: The present invention provides a pyrido[2,3-d]pyrimidine compound, or a pharmaceutically acceptable salt thereof, that inhibits Raf and, therefore, may be useful in treating cancer.
    Type: Application
    Filed: March 5, 2013
    Publication date: September 26, 2013
    Applicants: DECIPHERA PHARMACEUTICALS, LLC, ELI LILLY AND COMPANY
    Inventors: Matthew Carl Allgeier, Daniel L. Flynn, Michael D. Kaufman, Phenil J. Patel, Craig D. Wolfangel